Anebulo Pharmaceuticals (ANEB) Operating Income (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Operating Income of -$2.6 million for Q4 2025, down 1.23% year-over-year from -$2.7 million in Q4 2024, and down 15.91% quarter-over-quarter from -$2.3 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Operating Income (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Operating Income for 6 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income fell 1.23% year-over-year to -$2.6 million; the TTM figure through Dec 2025 stood at -$9.1 million (down 13.72% YoY), while the FY2025 annual figure was -$9.2 million, down 11.01% from the prior year.
- Operating Income retreated to -$2.6 million in Q4 2025 per ANEB's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$552131.0 in Q1 2021 and bottomed at -$3.8 million in Q4 2022.
- Historically, Operating Income has averaged -$2.2 million across 5 years, with a median of -$2.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income plunged 255.99% — and 2024, when it surged 46.26%.
- Anebulo Pharmaceuticals' Operating Income stood at -$1.1 million in 2021, then slumped by 255.99% to -$3.8 million in 2022, then gained by 27.61% to -$2.8 million in 2023, then gained by 6.24% to -$2.6 million in 2024, then declined by 1.23% to -$2.6 million in 2025.
- Business Quant data shows ANEB's Operating Income at -$2.6 million in Q4 2025, -$2.3 million in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.62 Mn |
| Sep 30, 2025 | -2.26 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.41 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -2.76 Mn |
| Sep 30, 2023 | -2.54 Mn |
| Jun 30, 2023 | -2.49 Mn |
| Mar 31, 2023 | -2.86 Mn |
| Dec 31, 2022 | -3.81 Mn |
| Sep 30, 2022 | -2.61 Mn |
| Jun 30, 2022 | -2.33 Mn |
| Mar 31, 2022 | -1.88 Mn |
| Dec 31, 2021 | -1.07 Mn |
| Sep 30, 2021 | -1.55 Mn |
| Jun 30, 2021 | -2.48 Mn |
| Mar 31, 2021 | -552,131.00 |